Form 4: BioCryst Director Alan Levin Receives Routine Equity Compensation Grants

BioCryst Pharmaceuticals, Inc. Director Alan G. Levin was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

Summary

• Alan G. Levin, a Director of BioCryst Pharmaceuticals, Inc. (BCRX), received automatic equity grants on June 12, 2025, as disclosed in a Form 4 filing.
• He was granted 12,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0, which are set to vest on the first anniversary of the grant date (June 12, 2026).
• Additionally, he received an automatic grant of 27,181 stock options with an exercise price of $10.4. These options become exercisable on June 12, 2026, and have an expiration date of June 12, 2035.
• Following these transactions, Alan G. Levin beneficially owns 64,271 shares of common stock and 27,181 stock options.
• The grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• A Power of Attorney dated June 11, 2025, was filed, authorizing Alane P. Barnes and Sara A. Mykrantz to prepare and submit SEC filings, including Forms 3, 4, and 5, on behalf of Alan G. Levin.

Sentiment

Score: 6

Explanation: The document reports routine equity compensation for a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or strategic position.

Positives

• The equity grants align the interests of Director Alan G. Levin with those of the company's shareholders, as the value of his compensation is directly tied to the company's stock performance.
• The grants are part of a standard, established compensation policy for non-employee directors, indicating a structured and transparent approach to corporate governance and director remuneration.

Risks

• The value of the granted Restricted Stock Units (RSUs) and stock options is subject to the future performance and volatility of BioCryst Pharmaceuticals, Inc.'s stock price.
• Stock options carry the inherent risk that they may expire unexercised or out-of-the-money if the company's stock price does not rise above the exercise price of $10.4 before the expiration date.

Future Outlook

This document primarily reports past equity compensation grants to a director and does not contain forward-looking statements regarding the company's financial performance, strategic direction, or operational guidance, beyond the specified vesting and exercisability dates of the granted securities.

Management Comments

• The equity grants were made "pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended."

Industry Context

This filing is a routine insider transaction report (Form 4) detailing equity compensation for a non-employee director. Such compensation structures, involving grants of Restricted Stock Units and stock options, are common practice across various industries, including biotechnology and pharmaceuticals, to align the interests of directors with long-term shareholder value creation. This specific filing does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to non-employee directors is a standard practice in the biotechnology and pharmaceutical industry, similar to compensation structures at companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN), which often use equity to incentivize long-term value creation.
• The specific mix of RSUs and options, and their vesting schedules (e.g., one-year vesting for RSUs, multi-year exercisability for options), aligns with typical governance practices aimed at retaining directors and linking their compensation to company performance over time.
• The exercise price of $10.4 for the options is likely based on the market price of BCRX stock on the grant date, a common and compliant method for option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the interests of Director Alan G. Levin with shareholders, as his compensation is tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The Restricted Stock Units granted to Alan G. Levin are scheduled to vest on June 12, 2026.
• The stock options granted to Alan G. Levin will become exercisable on June 12, 2026, and will expire on June 12, 2035.
• Alan G. Levin will continue to file Section 16 reports (Forms 3, 4, and 5) as required for his holdings and transactions in BioCryst Pharmaceuticals, Inc. securities.

Key Dates

Recommendation

Keywords

BioCryst Pharmaceuticals, BCRX, Alan G. Levin, Director, SEC Form 4, Stock Options, Restricted Stock Units, RSU, Equity Grant, Compensation Policy, Insider Transaction, Corporate Governance